Study guide
3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia
Key Takeaways Explain This Topic AI
Neonatal respiratory distress syndrome (RDS) results from primary deficiency of pulmonary surfactant produced by alveolar type II pneumocytes, leading to increased alveolar surface tension, atelectasis, and intrapulmonary shunting that is treated with animal-derived surfactant replacement.
Poractant alfa (Curosurf) is dosed at an initial dose of 200 mg/kg (2.5 mL/kg), followed by 100 mg/kg (1.25 mL/kg) every 12 hours prn, which demonstrates faster FiO2 reduction and lower mortality compared to 100 mg/kg initial regimens of calfactant (Infasurf, 105 mg/kg) or beractant (Survanta, 100 mg/kg).
Minimally invasive surfactant therapy (MIST) and less invasive surfactant administration (LISA) deliver surfactant via a thin intratracheal catheter during spontaneous breathing on continuous positive airway pressure (CPAP), significantly reducing mechanical ventilation days and BPD compared to standard intubation-surfactant-extubation (INSURE).
Postnatal systemic corticosteroids for BPD must be strictly timed: early systemic dexamethasone (< 7 days of life) is contraindicated due to increased rates of cerebral palsy, whereas the DART low-dose tapering protocol (cumulative 0.89 mg/kg over 10 days) facilitates extubation in ventilator-dependent infants after 1–2 weeks of life without neurodevelopmental harm.
Last updated: September 2026
3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia
Respiratory failure due to developmental immaturity of the pulmonary parenchyma remains the single most common reason for admission to the Neonatal Intensive Care Unit (NICU). The clinical continuum spans acute neonatal Respiratory Distress Syndrome (RDS) immediately following delivery to chronic Bronchopulmonary Dysplasia (BPD) weeks or months later. The Pediatric Pharmacy Specialist must possess in-depth mastery of surfactant biophysics, comparative pharmacology of animal-derived surfactant products, modern non-invasive delivery techniques, and evidence-based pharmacotherapy for chronic lung disease.
Pathophysiology of Respiratory Distress Syndrome (RDS)
RDS (historically termed hyaline membrane disease) is primarily a disease of developmental surfactant deficiency affecting premature infants. The incidence is inversely proportional to gestational age, occurring in roughly 80% to 90% of infants born at < 28 weeks, 50% to 60% at 29 to 32 weeks, and < 5% at > 34 weeks of gestation.
Surfactant Synthesis & Composition
Pulmonary surfactant is synthesized, stored in intracellular lamellar bodies , and exocytosed into the alveolar hypophase by alveolar type II pneumocytes beginning around 24 to 28 weeks of gestation, with mature alveolar pools typically achieved by 35 to 36 weeks. Structurally, pulmonary surfactant consists of:
Phospholipids (~80% to 85%) : Primarily dipalmitoylphosphatidylcholine (DPPC) , also known as disaturated phosphatidylcholine. DPPC contains two saturated palmitic acid chains that pack tightly at the air-liquid interface to generate near-zero surface tension upon alveolar compression.
Neutral Lipids (~8% to 10%) : Chiefly cholesterol, which modulates surfactant film fluidity and spreading dynamics.
Surfactant-Associated Proteins (~5% to 10%) :
Hydrophobic Proteins (SP-B and SP-C) : Essential for biophysical function. SP-B and SP-C accelerate the rapid insertion, spreading, and re-spreading of phospholipids into the monolayer during dynamic respiratory cycling. Genetic deficiency of SP-B is an autosomal recessive condition causing lethal neonatal respiratory failure curable only by lung transplantation.
Hydrophilic Proteins (SP-A and SP-D) : Calcium-dependent lectins (collectins) that function within the innate pulmonary immune system, opsonizing bacteria, viruses, and fungi while regulating alveolar inflammation.
Biomechanical Consequences: The Law of Laplace
The physical stability of spherical terminal alveoli is dictated by the Law of Laplace : P = 2 T r P = \frac{2T}{r} P = r 2 T
Where:
- P P P = Collapsing pressure required to keep the alveolus open
- T T T = Surface tension at the alveolar air-liquid interface
- r r r = Radius of the alveolus
In the absence of surfactant, surface tension ( T T T ) remains constant and high (~70 dynes/cm, equivalent to pure water). As an infant exhales, alveolar radius ( r r r ) decreases; according to the equation, the collapsing pressure ( P P P ) escalates dramatically. Smaller alveoli empty their volume into larger alveoli, precipitating diffuse microatelectasis, decreased functional residual capacity (FRC), intrapulmonary right-to-left shunting, severe ventilation-perfusion ( V / Q V/Q V / Q ) mismatch, hypoxemia, and mixed respiratory/metabolic acidosis. Alveolar epithelial injury and capillary endothelial leak lead to the exudation of fibrin and plasma proteins into the alveolar spaces, creating the classic "hyaline membranes" on histology.
Comparative Pharmacology of Exogenous Surfactant Preparations
Natural animal-derived surfactants are significantly superior to synthetic first-generation surfactants (which lacked surfactant proteins). Three natural surfactant products are currently approved in the United States:
Parameter Poractant alfa (Curosurf®) Calfactant (Infasurf®) Beractant (Survanta®)
Source Minced porcine (pig) lung extract Calf (bovine) lung bronchoalveolar lavage Minced bovine (cow) lung extract with synthetic additives
Phospholipid Concentration 80 mg/mL (highly concentrated) 35 mg/mL 25 mg/mL
Active Protein Content SP-B (~1%) and SP-C (~1%) SP-B (~0.65%) and SP-C (~0.65%) SP-B (< 0.1%) and SP-C (~1%) + added DPPC, palmitic acid, tripalmitin
Initial Dose 200 mg/kg (2.5 mL/kg) 105 mg/kg (3.0 mL/kg) 100 mg/kg (4.0 mL/kg)
Repeat Doses 100 mg/kg (1.25 mL/kg) q12h prn (up to 2 repeat doses) 105 mg/kg (3.0 mL/kg) q12h prn (up to 3 repeat doses) 100 mg/kg (4.0 mL/kg) q6h prn (up to 4 doses in 48h)
Instillation Volume Lowest volume (2.5 mL/kg) Intermediate (3.0 mL/kg) Highest volume (4.0 mL/kg)
Clinical Pearls Faster FiO 2 \text{FiO}_2 FiO 2 weaning; lower mortality vs 100 mg/kg poractant or beractant in clinical trials Natural lavage extract preserves high SP-B ratio; longer duration between doses Synthetic lipid fortification compensates for extraction losses; large volume can cause transient airway obstruction
Clinical Evidence & Selection Rationale
Randomized controlled trials and meta-analyses (including Cochrane systematic reviews) demonstrate that an initial poractant alfa dose of 200 mg/kg (yielding 2.5 mL/kg volume) provides significantly faster weaning of supplemental fraction of inspired oxygen ( FiO 2 \text{FiO}_2 FiO 2 ) and lower acute mortality before hospital discharge compared to initial 100 mg/kg regimens of beractant or calfactant. Furthermore, the lower instillation volume of poractant alfa (2.5 mL/kg vs 4.0 mL/kg for beractant) markedly reduces the incidence of transient endotracheal tube obstruction, bradycardia, and oxygen desaturation during intratracheal instillation.
Surfactant Handling & Administration Rules
Storage : Store refrigerated at 2°C to 8°C (36°F to 46°F) protected from light.
Warming : Bring vial to room temperature for roughly 20 to 30 minutes prior to administration. Never microwave or use artificial heat sources , as heat denatures the hydrophobic SP-B and SP-C tertiary protein structures.
Mixing : Inspect vial for discoloration or particulate matter. Gently invert the vial several times without shaking. Shaking causes extensive foaming and denatures the surfactant proteins.
Ventilator Management : Immediately post-instillation, alveolar compliance improves rapidly. Clinicians must actively monitor chest excursion and immediately wean peak inspiratory pressure (PIP) or tidal volume and FiO 2 \text{FiO}_2 FiO 2 to prevent pulmonary overdistension, pneumothorax, and pulmonary hemorrhage.
Surfactant Delivery Modalities: INSURE vs LISA/MIST
The historic paradigm of universal intubation and mechanical ventilation for surfactant delivery has been superseded by non-invasive delivery modalities designed to eliminate ventilator-induced lung injury (VILI): Surfactant Delivery Paradigms in Spontaneously Breathing Preterm Infants
- [ Preterm Infant on Non-Invasive CPAP with RDS ]
- |
- +---------------------------+---------------------------+
- | |
- INSURE Technique LISA / MIST Technique
- | |
- 1. Endotracheal Intubation 1. Maintain Infant on Non-Invasive CPAP
- 2. Surfactant Instillation via ETT 2. Direct / Video Laryngoscopy
- 3. Positive Pressure Ventilation 3. Thread Thin Vascular Catheter (16-18G)
- 4. Extubation to CPAP (< 1 hour) Through Vocal Cords into Trachea
- | 4. Instill Surfactant Slowly over 1-3 min
- Drawbacks: While Infant Breathes Spontaneously
- Exposure to positive pressure cycles 5. Immediately Remove Catheter
- Risk of failed extubation |
- Laryngeal / tracheal trauma Benefits:
- Zero positive pressure cycles
- Preserves native laryngeal braking
- Significant reduction in BPD / Death
INSURE (INtubation, SURfactant, Extubation) :
The infant is intubated, given endotracheal surfactant with positive pressure bagging or mechanical ventilation, and extubated directly to Continuous Positive Airway Pressure (CPAP) within 60 minutes. While superior to prolonged mechanical ventilation, INSURE still exposes immature alveolar sacs to cyclic positive pressure volutrauma.
LISA (Less Invasive Surfactant Administration) / MIST (Minimally Invasive Surfactant Therapy) :
The infant remains on non-invasive CPAP breathing spontaneously. Under direct or video laryngoscopy, a thin, flexible catheter (e.g., 16–18 gauge vascular catheter, Angiocath, or dedicated surfactant catheter) is threaded through the vocal cords into the mid-trachea. Surfactant is instilled over 1 to 3 minutes while the infant's spontaneous breaths distribute the drug into the distal lung via negative inspiratory pressure. Landmark randomized trials (such as the OPTIMIST-A trial) have demonstrated that LISA/MIST significantly reduces the need for mechanical ventilation within the first 72 hours of life and lowers the composite outcome of death or BPD at 36 weeks postmenstrual age.
Bronchopulmonary Dysplasia (BPD): Pathogenesis & Modern Classification
BPD represents the chronic, maladaptive pulmonary sequel of prematurity. In the modern era of surfactant replacement and gentle ventilation, classic BPD (severe airway fibrosis and smooth muscle hypertrophy from aggressive ventilation) has been replaced by "New BPD" —characterized by arrest of alveolar and vascular development (fewer, simplified, hyper-enlarged alveoli with a severely decreased surface area for gas exchange and dysmorphic capillary networks).
The Jensen 2021 NICHD BPD Diagnostic Criteria
In 2021, the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network refined the diagnostic definition and severity grading of BPD, evaluated strictly at 36 weeks postmenstrual age (PMA) :
No BPD : Spontaneously breathing on room air without respiratory support at 36 weeks PMA.
Grade 1 BPD : Requiring low-flow nasal cannula ≤ 2 L/min \le 2\text{ L/min} ≤ 2 L/min supplemental oxygen.
Grade 2 BPD : Requiring nasal cannula > 2 L/min > 2\text{ L/min} > 2 L/min or non-invasive positive airway pressure (NCPAP, NIPPV).
Grade 3 BPD : Requiring invasive mechanical ventilation via endotracheal tube.
- Prevention & Pharmacotherapy of BPD
- 1. Caffeine Citrate Prophylaxis & The CAP Trial
Initiation of caffeine citrate within the first 72 hours of life (and frequently < 24 hours) is standard of care in VLBW neonates (< 1,250 g). The landmark Caffeine for Apnea of Prematurity (CAP) trial enrolled 2,006 VLBW infants, demonstrating that early caffeine therapy:
Significantly reduced the incidence of BPD (47% in caffeine group vs 63% in placebo group, p < 0.001 p < 0.001 p < 0.001 ).
Significantly accelerated weaning from mechanical ventilation and CPAP (mean reduction of 1 to 2 weeks).
Improved neurodevelopmental outcomes at 18 to 21 months of corrected age, including a significant reduction in cerebral palsy (OR 0.58) and cognitive delay.
2. Postnatal Systemic Corticosteroids: Balancing Efficacy & Neurotoxicity
Inflammation drives alveolar arrest in BPD. However, corticosteroids present a profound clinical trade-off between pulmonary improvement and neurodevelopmental toxicity:
The Danger of Early High-Dose Dexamethasone (< 7 Days of Life):
During the 1990s, neonatologists utilized early high-dose dexamethasone (0.5 mg/kg/day tapering over 4 weeks) starting within the first week of life to prevent BPD. Subsequent long-term randomized follow-up trials revealed a catastrophic increase in cerebral palsy (relative risk 1.7 to 2.0) , adverse neuromotor development, gastrointestinal perforation, and stunted somatic/head growth. Consequently, the American Academy of Pediatrics (AAP) strictly contraindicated early routine systemic dexamethasone for BPD prevention.
The DART Low-Dose Dexamethasone Protocol (>= 7 to 14 Days of Life):
For infants who remain ventilator-dependent with evolving severe BPD beyond the first 1 to 2 weeks of life, the Dexamethasone: A Randomized Trial (DART) protocol established a safe, low-dose, 10-day tapering regimen that successfully facilitates extubation without neurodevelopmental harm:
- Day of Therapy Dexamethasone Daily Dose Administration Schedule
- Days 1 to 3 0.15 mg/kg/day Divided every 12 hours (0.075 mg/kg/dose IV/PO q12h)
- Days 4 to 6 0.10 mg/kg/day Divided every 12 hours (0.05 mg/kg/dose IV/PO q12h)
- Days 7 to 8 0.05 mg/kg/day Administered as a single daily dose (0.05 mg/kg/dose q24h)
- Days 9 to 10 0.02 mg/kg/day Administered as a single daily dose (0.02 mg/kg/dose q24h)
- Total Cumulative Dose 0.89 mg/kg Completed over exactly 10 days
Clinical Outcomes: The DART trial achieved significantly higher extubation rates by day 10 compared to placebo (60% vs 12%, p < 0.001 p < 0.001 p < 0.001 ) and demonstrated no statistically significant differences in cerebral palsy, death, or major neurodevelopmental disability at 2 years of age.
Alternative Steroids: Hydrocortisone & Inhaled Corticosteroids:
Hydrocortisone : The multicenter PREMILOC trial evaluated early, physiological-dose hydrocortisone (1 mg/kg/day divided q12h for 7 days, then 0.5 mg/kg/day for 3 days) in infants born at 24 to 27 weeks gestation. Results showed significantly improved survival without BPD at 36 weeks PMA without neurodevelopmental harm at 2 years of age. However, when hydrocortisone is combined with indomethacin for PDA closure, the risk of spontaneous intestinal perforation (SIP) increases dramatically.
Inhaled Corticosteroids (Budesonide) : Evaluated in the European NEUROSIS trial to target pulmonary inflammation while avoiding systemic toxicity. While inhaled budesonide reduced BPD rates, long-term follow-up noted an unexplained, borderline increase in mortality in the budesonide arm, preventing widespread adoption as universal prophylaxis.
3. Diuretic Pharmacotherapy in Established BPD
Diuretics are widely employed in the NICU to treat acute pulmonary edema, decrease interstitial lung fluid, and enhance dynamic compliance in infants with evolving BPD. However, chronic therapy carries substantial metabolic hazards:
Loop Diuretics (Furosemide):
Mechanism : Inhibits the Na + / K + / 2 Cl − \text{Na}^+/\text{K}^+/2\text{Cl}^- Na + / K + /2 Cl − symporter in the thick ascending limb of Henle. Dose: 1 mg/kg IV or 2 mg/kg PO.
Chronic Complications : Profound urinary calcium wasting causing hypercalciuria, nephrocalcinosis (renal parenchymal and medullary calcium deposition detectable on ultrasound), nephrolithiasis, and osteopenia of prematurity (metabolic bone disease with pathological rib fractures). Additionally causes hypokalemic, hypochloremic metabolic alkalosis and ototoxicity (synergistic with aminoglycosides).
Thiazide & Potassium-Sparing Diuretics (Chlorothiazide + Spironolactone):
Mechanism : Chlorothiazide (10–20 mg/kg/dose PO q12h) inhibits the Na + / Cl − \text{Na}^+/\text{Cl}^- Na + / Cl − cotransporter in the distal convoluted tubule; spironolactone (1–1.5 mg/kg/dose PO q12h) competitively antagonizes aldosterone in the cortical collecting tubule.
Renal Advantage : Unlike loop diuretics, thiazides enhance distal tubular calcium reabsorption , sparing renal calcium and mitigating the risk of nephrocalcinosis and bone demineralization. Combination chlorothiazide/spironolactone is preferred for chronic outpatient and subacute inpatient management of pulmonary edema in established BPD, requiring regular monitoring of serum potassium, sodium, and chloride.